DSMB recommends continuation of Phase III trial of PTX3003 for CMT1A disease

Pharnext S.A.S. (Euronext:ALPHA) said an independent DSMB recommended for the second time continuation of the Phase III PLEO-CMT trial of PXT3003 (PXT-3003) to treat Charcot-Marie-Tooth Type IA (CMT1A) disease. The double-blind, placebo-controlled, international trial is evaluating 2 dose levels of twice-daily oral PXT3003 for 15 months in 323 patients.

The company plans to present top-line data in mid-2018...